Evidence map›Paper›PMID 32753312›Full record

ArticleJournal of hepatology2020

Erratum to: 'Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance' (J Hepatol 2019; 71(1): 14-24).

Sabrina J Merat, Camille Bru, Dorien van de Berg, Richard Molenkamp, Alexander W Tarr, Sylvie Koekkoek, Neeltje A Kootstra, Maria Prins, Jonathan K Ball, Arjen Q Bakker and 4 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Sabrina J MeratAIMM Therapeutics, Amsterdam, the Netherlands.
Camille BruAIMM Therapeutics, Amsterdam, the Netherlands.
Dorien van de BergAIMM Therapeutics, Amsterdam, the Netherlands.
Richard MolenkampDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Alexander W TarrSchool of Life Sciences, The University of Nottingham, Nottingham, UK; NIHR Nottingham BRC, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
Sylvie KoekkoekDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Neeltje A KootstraDepartment of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Maria PrinsPublic Health Service of Amsterdam, Amsterdam, the Netherlands; Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Jonathan K BallSchool of Life Sciences, The University of Nottingham, Nottingham, UK; NIHR Nottingham BRC, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
Arjen Q BakkerAIMM Therapeutics, Amsterdam, the Netherlands.
Menno D de JongDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Hergen SpitsAIMM Therapeutics, Amsterdam, the Netherlands.
Tim BeaumontAIMM Therapeutics, Amsterdam, the Netherlands. Electronic address: tbeaumont@aimmtherapeutics.com.
Janke SchinkelDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: J.Schinkel@amc.uva.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID32753312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.